01. Letter from the President

Dear Friends,

I hope this finds you well and that you all have had a chance to enjoy some relaxing summer vacation.

For those of you who were able to participate in the June ECFS Conference in Basel, I am sure you will agree that it was a great success, and I would again like to thank the conference President Marc Chanson, and the Vice Presidents, Alexander Moeller and Juerg Barben for their contribution to the event. I would also like to thank the Cystic Fibrosis Association of Switzerland and all their considerable and enthusiastic support. My sincere thanks go to the Scientific Committee who produced an excellent programme, and to the speakers, moderators and presenters for their superb contribution.

The ECFS continued its tradition of awarding Travel Grants to young researchers based on the merit of their submitted abstracts, and we were delighted to welcome the 3 Young Investigator Awardees to the Closing Ceremony. All the award winners also received a 1 year free membership subscription to the ECFS.

Young Investigator Awards 2016:
Lionelle Nkam (FR) Vilma Rautemaa (UK)
Katie Bayfield (UK)
To honour the enormous contribution of Prof. Gerd Döring, the ECFS has initiated a Gerd Döring Award in 2015 that is given annually to honour an exceptional early career young European scientist. This award includes a monetary grant of €5000 to support research. This year, the Award was presented to Gillian Lavelle (IE) for her manuscript entitled “The basophil surface marker CD203c identifies Aspergillus species sensitisation in patients with cystic fibrosis”. It describes for the first time the use of the novel basophil activation test for the rapid identification of Aspergillus fumigatus (Af)-sensitisation in people with CF, a state associated with poorer lung function. 

More information on the ECFS Awards:

Once again, speakers at this year’s conference were asked to make their presentations (slides) available on the ECFS website (for members only) and these can be viewed by signing in under the “MY ECFS” tab in the top banner of our website www.ecfs.eu.

We have some changes in the ECFS Board and I would like to warmly welcome Isabelle Sermet and congratulate Margarida Amaral who is starting her second term. It’s a pleasure to count them amongst the Board and we look forward to their input. Again, I would like to thank Tanja Pressler, our departing Board member for her commitment and support during her term in office.

We are well into the planning for the Basic Science Conference which will be held in Albufeira in Portugal (29 March - 01 April 2017), and the annual conference which will be held 07-10 June 2017 in Seville, Spain. Programmes for both conferences will be available soon and we hope that you will take an active part in these events and consider submitting your best work for presentation and discussion. The abstract submission deadline for the conference in Seville will be 20 January 2017. More information about the conferences can be found on our website.

I would like to thank those members who participated in this year’s Annual General Meeting in Basel, and you will find the minutes from the meeting included in this Newsletter.

As discussed at the AGM in Basel, our goal is to see 95% of patients with CF in every country to have 2 mutations identified by 2018. Please make use of the service and inform those around you about the ECFS CFTR gene sequencing service. More information later in the newsletter.

Finally, the EMA published a Concept paper on the need for revision of the guideline on the clinical development of medicinal products for the treatment of cystic fibrosis (CHMP/EWP/9147/08). This concept paper highlights items that have been identified and would need to be addressed in the revised guideline. The paper is open for comments (deadline of 31 October 2016).

As always, I would like to remind you to please feel free to send us articles that you would like to have included in forthcoming newsletters as this provides a great vehicle for communication.

Best wishes,

Kris De Boeck, ECFS President
02. Upcoming Events

- ECFS Board Meeting 26 October 2016 - Orlando, Florida, USA
- 30th North American Cystic Fibrosis Conference 27-29 October 2016 - Orlando, Florida, USA
- ECFS Winter Board Meeting - 25 January 2017 - Lisbon, Portugal
- ECFS CTN Steering Group Meeting - 26-27 January 2017 - Lisbon, Portugal
- ECFS Standards of Care Meeting - 26 January 2017 - Lisbon, Portugal
- ECFS Patient Registry Steering Group Meeting - 27 January 2017 Lisbon, Portugal
- ECFS Diagnostic Network Working Group Meeting - 16- 18 February 2017, Ljubljana, Slovenia
- 11th European Young Investigators Meeting - 15-17 February 2017, Paris, France
- ECFS 14th Basic Science Conference - 29 March - 01 April 2017, Albufeira, Portugal
- ECFS Board Meeting - 06 June 2017 - Seville, Spain
- 40th European CF Conference - 07-10 June 2017 - Seville, Spain

03. Deadlines

- EMA Open consultation 31 October 2016
- Abstract submission ECFS Conference Seville 20 January 2017
- Abstract submission 14th ECFS Basic Science conference 20 January 2017
- Nomination ECFS Award 15 February 2017
- Nomination Gerd Döring Award 15 February 2017
- Nomination ECFS Elections 30 March 2017

04. EMA Concept paper open for public consultation

The EMA would like to draw attention to the publication of the Concept paper on the need for revision of the guideline on the clinical development of medicinal products for the treatment of cystic fibrosis (CHMP/EWP/9147/08) open for public consultation.

This concept paper highlights items that have been identified and would need to be addressed in the revised guideline. We invite you to submit your comments, especially if you identify any overlooked issues.

The public consultation will run until 31 October 2016. Comments should be provided using this template and sent to respiratorydg@ema.europa.eu.

Following this time period, EMA plans to release the draft Guideline for 6 months public consultation in October 2017, ending in April 2018.
05. CFTR gene sequencing service

As presented at the AGM in Basel, the ECFS ambitious goal is to see 95% of patients with CF in every country to have 2 mutations identified by 2018. The ECFS provides a service for highly parallel sequencing of the complete CFTR gene (including intronic and promoter regions) in patients with confirmed CF (maximum 5 patients per individual site) in whom a disease-causing mutation was not found on both CFTR genes. Please make use of the service and inform those around you about it! More information and request form can be found at https://www.ecfs.eu/ecfs_dnwg

06. Job postings

The BioSys PhD Programme in Life Sciences (http://biosys.campus.ciencias.ulisboa.pt) is an international programme for talented and highly motivated students of any nationality.

Research at the BioSys covers a range of topics with an interdisciplinary nature by applying integrative functional genomics and innovative research approaches. The programme supports its students in their scientific explorations, providing state-of-the-art equipment, expert scientific advisors, and extensive scientific and administrative support.

Applications for the 2016-2017 edition are open. Click here (link is http://biosys.campus.ciencias.ulisboa.pt/) to have more details. Deadline for application 21 October 2016.

07. ECFS Education

The mission statement of the European Cystic Fibrosis Society is to improve survival and quality of life for people with CF by promoting high quality research, education and care. The ECFS has developed a number of educational activities so far: the ECFS annual conference, the Basic Science conference, the Journal of Cystic Fibrosis, development of guidelines and CF courses.

The ECFS is now working on the development of an educational website which will enhance the already existing activities and streamline all educational resources. In addition, the platform will allow for the development of compelling educational modules on different aspects of cystic fibrosis. Please contact us if you have a project or ideas for the educational website, we will be happy to discuss!
08. ECFS Board changes

We are happy to welcome Isabelle Sermet and Margarida Amaral to the ECFS Board. We would like to take this opportunity to warmly thank Tanja Pressler for her commitment through the years.

09. JCF Impact factor

The journal impact factors for 2015 have been announced by Thomson Reuters. The journal impact factor is a measure of how frequently papers from that particular journal are quoted. It is a pleasure to announce that the journal impact factor for the Journal of Cystic Fibrosis has increased this year from 3.475 to **3.853**. This is the highest our impact factor has been since the journal started and reflects the high quality of papers published now in JCF.

10. JCF Research News

CF Research News offers lay version summaries of the most recent articles published in the Journal of Cystic Fibrosis. The aim of this new initiative is to bridge the gap between people with CF and the researchers investigating CF and how best to treat those with the condition. We aim to provide access to all scientific work published in the Journal of Cystic Fibrosis (JCF) to patients, parents, relatives, friends and caregivers of people with CF.

To access CF Research News click [here](#)
11. ECFS has got talent

At the Get-Together event that we will organise in Seville on the Friday 09 June 2017, we would like to put the spotlights on our ECFS members willing to show their talents. If you are a guitarist, a singer, a magician,… please get in touch with us, we would love to hear from you!

12. ECFS Tomorrow

The third edition of the EFCS Tomorrow in Basel was a great success.

Over the four days of conference, people from our multidisciplinary community researching and treating Cystic Fibrosis could meet at the ECFS Tomorrow Lounge to exchange ideas. Several interactive workshops and a debate were organised by Special Interest Groups and the feedback received indicated that all were enthusiastic about the initiative.

We also had our second edition of our ECFS Tomorrow Networking Event. During this relaxing evening friends and colleagues had the opportunity to meet new people and exchange experiences.

We also organised a quiz with a free registration to the Annual conference in Seville next year… and the winner is Rebecca Dobra, London, UK.

We are finalising the Seville programme, get ready for changes and look out for more information in the coming months!
13. Annual General Meeting Minutes

Minutes of the Annual General Meeting of the European Cystic Fibrosis Society

39th European Cystic Fibrosis Conference, Basel, Switzerland, 10th June 2016

Presiding Officer: Prof. Kris De Boeck

The meeting was opened at 18.30.
Number of Participants: 40

President’s Report

Prof. Kris De Boeck welcomed the ECFS members present and thanked them for their participation in the meeting. She hopes for higher number of participants at the next AGM in Seville.

She presented a slide listing the current ECFS Projects and Working Groups, and noted that reports on these activities had been provided ahead of the meeting and Coordinators of these projects would be ready to answer questions on their activities later on in the meeting.

Regarding ECFS conferences, she reported that about 2000 delegates had registered for the Basel conference and that 467 abstracts had been submitted. She took the opportunity to thank the Conference President and Conference Vice Presidents and all the other organizers for their contribution to a smooth preparation of the conference.

She went on to provide an overview of the ECFS activities over the last year, beginning with the Steering Committee meetings of the CTN and ECFSPR in January and the ECFS Diagnostic Network Working Group meeting in London in February. She mentioned the highly successful Basic Science conference held in Pisa, Italy, where a record number of attendees and abstract submissions were recorded.

The President then presented the programme of activities for 2016-2017 to include:

• ECFS Autumn Meeting, Orlando 26 October 2016
• CTN Steering Group Meeting, Lisbon 26-27 January 2017
• ECFS Winter Board Meeting, Lisbon 25 January 2017
• Registry Steering Group Meeting, Lisbon 27 January 2017
• ECFS Diagnostic Network WG Meeting, Ljubljana 16-18 February 2017
• 14th ECFS Basic Science Conference, Albufeira 29 March - 1 April 2017
• Young Investigators Meeting, Paris 15-17 February 2017
• 40th European CF Conference, Seville 7-10 June 2017

Prof. De Boeck presented the plans ahead for the society.

• Continuing CFTR gene sequencing service with a goal to see 95% of patients with CF in every country to have 2 mutations identified by 2018
• Defining research priorities: a strategic plan to maximize progress in CF therapies is being designed under the leadership of Jane Davies, London, UK
• Education: ECFS has ambitious projects and an educational portal is being developed under the leadership of Daniel Peckham, Leeds, UK
• Implementing mental health guidelines: the ECFS recently approved a new working group dedicated to mental health
• The ECFS website will be refurbished and will also include diary dates of meetings and a page dedicated to announcements for positions within CF.
• ECFS Book: the next ECFS book will be dedicated to infants and young children. Editors are sought for this new initiative and Prof De Boeck encouraged ECFS Members to volunteer.

• Further collaboration across continents

Prof. De Boeck presented some initiatives to further encourage participation of ECFS members to the activities of the Society.

• ECFS community bulletin board (Positions offered, jobs wanted, collaboration asked for, etc)

• Suggestion box for ECFS members at the ECFS conference (Suggestions for project opportunities, questions to ECFS board, nominations of candidates for future ECFS board positions, etc.)

• ECFS elections via e-voting also available during the ECFS conference

• Expansion of ECFS Tomorrow lounge activities

• Expansion of Special Interest Groups associated with ECFS

She thanked the departing ECFS Board Member Tania Pressler for her commitment over the years and ended her report by thanking the ECFS Membership, the National Patient Organisations, the Pharmaceutical Industry, and International collaborators for their continuing support of ECFS activities.

The audience was asked for any questions: None received.

Secretary’s Report

Prof. Harm Tiddens reported the preliminary membership numbers for 2016 (May) were 925, an increase in comparison with the figures reported at the same time frame in 2015. One of the reasons for this was the introduction of conference registration and membership subscription available to all attendees.

In view of the healthy financial situation of the Society, he was happy to inform the membership that there would be no increase to the standard subscription fee in 2017; it will remain at Euro 120. There will be a continued lower rate for some categories of members who do not wish to receive the Journal of Cystic Fibrosis (JCF):

• Allied Health Professionals, PhD Students and Post Docs - 50 € (*)
• Retired members still actively engaged in an ECFS Project or Working Group - Free (*)

(*) no JCF subscription associated with this rate

The discounted 3 years subscription (300 € instead of 360 €) introduced in 2015 will be offered as a membership possibility for the years 2017-2018-2019

He announced the introduction of a corporate membership rate for colleagues from the industry set at 220 € and offering full membership benefits but no voting rights.

He thanked the departing Board members, Tacjana Pressler and Margarida Amaral for their invaluable input over the years.

The new Board members elected are: Margarida Amaral and Isabelle Sermet. Given the fact that the number of candidates corresponded to the number of positions available, no online secured voting was organised. The low number of candidates was disappointing and he encouraged the membership to stand for elections in the future.

The audience was asked for any questions: None received.

Treasurer’s Report

Prof. Tania Pressler presented the audited ECFS Financial statement for the year 2015. The result of the year was very favourable, with a surplus of € 118,234 resulting in a positive balance for the Society’s net assets of € 2,576,205 at 31st December 2015. Prof. Pressler informed the AGM that the full audited accounts will be posted on the website.
**Update on Journal of Cystic Fibrosis**

Dr. Scott Bell reported on developments of JCF since the start of his office. The acceptance rate is currently at 26%.

Based on the page budget, the number of paper published per annum should be in the region of 110 - 120.

There has been a steady increase of submitted articles (178 as of 6 June 2016) and a corresponding rise in the number of Science Direct downloads.

New initiatives and recent changes include:

- Ongoing renewal of Editorial Board (Carlo Castellani, Cliff Taggart)
- Streamline MS handling … though finding ‘reviewers’ an ongoing challenge
- Editorials in each issue
- Bundled in themes
- “Invited Review” series (Endpoints)
- Highlights (“News” section)
- Lay Journal (“CF Research News”)
- Best of at ECFC (Saturday 11 June) and NACFC
- Social media and the Journal - launching Twitter

**Report from ECFS CTN**

Dr. Tim Lee presented a graph demonstrating the progression of studies conducted by the CTN since 2009.

He also presented the evolution of the CTN services including number of protocols reviewed and number of feasibility checks performed.

He reported on a recent survey of the CTN sites related to site capacity. Data will be used to apply for some targeted additional research infrastructure support from our European and North American partners.

**Report from ECFS Patient Registry**

Dr. McKone reported on the activities of the ECFS Patient Registry (ECFSPR).

The ECFSPR is expanding its coverage with 28 countries participating and over 42,000 CF patients.

He reported that the ECFSPR aimed to publish the 2014 data report in the fall 2016.

He presented a project for a benchmarking tool that will be developed allowing for:

- Comparison between centres and centre-country
- Comparison with previous years
- Graphs in real time

He also reported on the recent development of a 2013 at a glance report in collaboration with CF Patient Organizations.

Finally, Dr. McKone thanked the project’s sponsors and collaborators.

**Report from ECFS Standards of Care**

Pavel Drevinek reported on the progress of the Standards of Care project.

The best practice subgroup is reviewing and updating the 2014 Standards of Care. The goal is to get the document for review by the ECFS Board in March 2017 and ready for publication in May 2017.

The Quality Management subgroup organized its second course in Basel. The group is developing a module in the ECFSTracker for benchmarking across countries/centres.

The centre framework subgroup is focusing on Standards of care in Eastern Europe. Analysis of a recent survey is underway.

**Reports from ECFS Working Groups**
Prior to the Annual General Meeting, members had been sent the progress reports from the ECFS Working Groups.
Dr Trudy Havermans presented the newly formed ECFS Mental Health working group. The working group is lead by Janice Abbott and Trudy Havermans and is working closely with the CFF Mental Health group.

Current Working Groups:
- Diagnostics Network Working Group
- Exercise Working Group
- Neonatal Screening Working Group
- Cystic Fibrosis Molecular & Cell Biology and Physiology Basic Science Working Group
- Mental Health Working Group

The audience was asked for any questions: None received.

Special Interest Groups

Prof De Boeck reported on Special Interest Groups and their affiliation with ECFS:
- ECFS affiliated:
  - ECFS Nurse Specialist Interest Group (ECFS NSiG)
  - European Cystic Fibrosis Pharmacy Group (ECFPG)
  - ECFS Psychosocial Working Group
- not ECFS affiliated:
  - International Physiotherapy Group for Cystic Fibrosis
  - European Cystic Fibrosis Nutrition Group

Annual Conference 2017
A slide was shown presenting the 40th ECFS conference, to be held in Seville, Spain, 7-10 June 2017.

Questions/Comments received: None

Any Other Business
None

With no further items being raised, the meeting ended at 19.30.


The ECFS would like to thank all those who took the time to answer the ECFS 2016 Survey after the conference in Basel. The answers and comments help us to keep on improving our conferences. As announced, three free registrations to the next ECFS Conference in Seville were selected from the respondents.

We congratulate the winners:
- Yulia Gorinova, Moscow, RU
- Roger Lundmark, Basel CH
- Elena Schneider, Sydney, AU

15. Current references in CF

Please scroll to next page for full list
Nyabam S., Wang Z., Thibault T., Olsusey A., Basar R., Marshall L., Griffin M.
A novel regulatory role for tissue transglutaminase in epithelial-mesenchymal transition in cystic fibrosis
Biochimica et Biophysica Acta-Molecular Cell Research 2016; 1863: 2224 - 2244

Pincikova T., Svedin E., Domsen E., Flodstrom-Tullberg M., Hjelte L.
Cystic fibrosis bronchiolar epithelial cells have impaired ability to activate vitamin D

Rymut SM., Kampman CM., Corey DA., Endres T., Cotton CU., Kelley TJ.
Ibuprofen regulation of microtubule dynamics in cystic fibrosis epithelial cells
American Journal of Physiology-Lung Cellular and Molecular Physiology 2016; 311: L317 - L327

CFTR

Atlante A., Favia M., Bobba A., Guerra L., Casavola V., Reshkin SJ.
Characterization of mitochondrial function in cells with impaired cystic fibrosis transmembrane conductance regulator (CFTR) function
Journal of Bioenergetics and Biomembranes 2016; 48: 197 - 210

Billeta A., Jia Y., Jensen TJ., Hou YX., Chang XB., Riordan JR., Hanrahan JW.
Potential sites of CFTR activation by tyrosine kinases
Channels 2016; 10: 247 - 251

Role of interaction and nucleoside diphosphate kinase b in regulation of the cystic fibrosis transmembrane conductance regulator function by camp-dependent protein kinase a
PLoS One 2016; 11: 3:e0149097 -

Cantin AM.
Cystic Fibrosis Transmembrane Conductance Regulator Implications in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Annals of the American Thoracic Society 2016; 13:

Latoundine Analogs Restore F508del-Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity
Molecular Pharmacology 2016; 90: 65 - 79

Cui GY., Khazanov N., Stauffer BB., Infield DT., Imhoff DY., Birault V., Hanrahan JW., Brochiero E., Sauve R.
Pore dilatation increases the bicarbonate permeability of CFTR, PAR1 and glycine receptor anion channels

Hollywood JA., Lee CM., Seallan MF., Harrison PT.
Analysis of gene repair tracts from Cas9gRNA double-stranded breaks in the human CFTR gene
Scientific Reports 2016; 6: ArNo: 32230

Pore dilatation increases the bicarbonate permeability of CFTR, ANO1 and glycine receptor anion channels

Monomerization and ER Reclopolization of GRAP Is a Requisite for Unconventional Secretion of CFTR
Traffic 2016; 17: 733 - 753

Investigating CFTR and KCa3.1 Protein/Protein Interactions

Kleine ML., Sane AT., Garafalo C., Levy E.
Targeted CFTR gene disruption with zinc-finger nucleases in human intestinal epithelial cells induces oxidative stress and inflammation

Lobo MJ., Amaral MD., Zaccolo M., Farinha CM.
EPAC1 activation by cAMP stabilizes CFTR at the membrane by promoting its interaction with NHERF1
Journal of Cell Science 2016; 129: 2599 - 2612
Lucarelli M., Bruno SM., Pierandrei S., Ferraguti G., Testino G., Truglio G., Strom R., Quattrucci S.
The Impact on Genetic Testing of Mutational Patterns of CFTR Gene in Different Clinical Macrocategories of Cystic Fibrosis
Journal of Molecular Diagnostics 2016; 18: 554 - 565
Mayer-Hambliett N., Boyle M., VanDevanter D.
Advancing clinical development pathways for new CFTR modulators in cystic fibrosis
Thorax 2016; 71: 454 - 461
Miere C., Hewitson H., Wood V., Kadeva N., Cornwell G., Codognotto S., Stephenson E., Ilic D.
Generation of KCLl021 research grade human embryonic stem cell line carrying a Delta F508 mutation in the CFTR gene
Stem Cell Research 2016; 16: 177 - 179
Mihalýi C., Toroczk B., Csanyadi L.
Obligate coupling of CFTR pore opening to tight nucleotide-binding domain dimerization
eLife 2016; 5: ArNo: e18164
Moisan S., Berlivet S., Ka C., Le Gac G., Dostie J., Ferec C.
Analysis of long-range interactions in primary human cells identifies cooperative CFTR regulatory elements
Nucleic Acids Research 2016; 44: 2564 - 2576
Ong T., Ramsey BW.
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator
Pediatric Clinics of North America 2016; 63: 751 - +
Palma AG., Galizia L., Kotsias BA., Marino GL.
CFTR channel in oocytes from Xenopus laevis and its regulation by xShroom1 protein
Pflügers Archiv-European Journal of Physiology 2016; 468: 871 - 880
Qian F., Liu L., Liu ZZ., Lu CB.
The Pore Architecture of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Revealed by Co-Mutation in Pore-Forming Transmembrane Regions
Physiological Research 2016; 65: 505 - 515
Ramli N.S.K., Giribabu N., Muniandy S., Salleh N.
Testosterone regulates levels of cystic fibrosis transmembrane regulator, adenylate cyclase, and cAMP in the seminal vesicles of orchidectomized rats
Theriogenology 2016; 85: 238 - 246
Shah VS., Ernst S., Tang XX., Karp PH., Parker CP., Ostegdaard LS., Welsh MJ.
Relationships among CFTR expression, HCO3- secretion, and host defense may inform gene- and cell-based cystic fibrosis therapies
Proceedings of the National Academy of Sciences of the United States 2016; 113: 5382 - 5387
Sherwood CL., Boitano S.
Airway epithelial cell exposure to distinct e-cigarette liquid flavorings reveals toxicity thresholds and activation of CFTR by plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR
Cell Death and Differentiation 2016; 23: 1380 - 1393
van der Mark VA., de Jonge HR., Chang JC., Ho-Mok KS., Duijst SJ., Vidovic D., Carlon MS., Elferink RPJO., Paulusma CC.
The phospholipid flipase ATP8B1 mediates apical localization of the cystic fibrosis transmembrane regulator
Biochimica et Biophysica Acta-Molecular Cell Research 2016; 1863: 2280 - 2288
Ribosomal Stalk Protein Silencing Partially Corrects the Delta F508- CFTR Functional Expression Defect
PLoS Biology 2016; 14: 5:e1002462
Vetter AJ., Karamyshev AL., Patrick AE., Hudson H., Thomas PJ.
N-Acetyltransferases and Regulation of CFTR Expression
Vetter A.J., Karamyshev A.L., Patrick A.E., Hudson H., Thomas P.J.
N-acetyl-acyltransferases and regulation of CFTR expression
PLoS One 2016; 11: 5:e0155430 -
Watson MJ., Lee SL., Marklew AJ., Gilmore RC., Gentzsch M., Sassano MF., Gray MA., Tarran R.
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Uses its C-Terminus to Regulate the A2B Adenosine Receptor
Scientific Reports 2016; 6: ArNo: 27390
Xue RQ., Gu H., Qiu YM., Guo Y., Korteweg C., Huang J., Gu J.
Expression of Cystic Fibrosis Transmembrane Conductance Regulator in Ganglia of Human Gastrointestinal Tract
Scientific Reports 2016; 6: ArNo: 30926
Yan C., Lang Q., Liao HJ., Jiang X., Ming Y., Sun HQ., Xu WM.
CFTR Deletion in Mouse Testis Induces VDAC1 Mediated Inflammatory Pathway Critical for Spermatogenesis
PLoS One 2016; 11: 8:e0158994
Yang R., Kerschner JL., Gosalia N., Neems D., Gorsic LK., Sohma Y., Hwang TC.
Differential contribution of cis-regulatory elements to higher order chromatin structure and expression of the CFTR locus
Nucleic Acids Research 2016; 44: 3082 - 3094
Yu VC., Sohna Y., Hwang TC.
On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator
Zwick M., Esposito C., Hellstern M., Seelig A.
On the mechanism of gating defects caused by the R117H mutation in cystic fibrosis transmembrane conductance regulator
Journal of Biological Chemistry 2016; 291: 14483 - 14498
Clinical
Adler FR., Liau TG.
The Dynamics of Disease Progression in Cystic Fibrosis
Bourke SJ., Booth Z., Doe S., Anderson A., Rice S., Gascoigne A., Quibell R.
A service evaluation of an integrated model of palliative care of cystic fibrosis
Palliative Medicine 2016; 30: 698 - 702
Diabetes

Armaghanian, N., Brand-Miller, J.C., Markovic, T.P., Steinbeck KS.
Hypoglycaemia in cystic fibrosis in the absence of diabetes: A systematic review
Journal of Cystic Fibrosis 2016; 15: 274 - 284

Boudeva V., Coriat A., Desjardins K., Rabasa-Lhoret R.
Glycated hemoglobin cannot yet be proposed as a screening tool for cystic fibrosis related diabetes
Journal of Cystic Fibrosis 2016; 15: 258 - 260

Burgess JC., Bridges N., Banya W., Gyi KM., Hodson ME., Bilton D., Simmonds NJ.
HbA1c as a screening tool for cystic fibrosis related diabetes

Burgess JC., Bridges N., Winston B., Gyi KM., Hodson ME., Bilton D., Simmonds NJ.
HbA1c as a screening tool for cystic fibrosis related diabetes
Response
Journal of Cystic Fibrosis 2016; 15: 265 - 266

Coriati A., Dubois CL., Phaneuf M., Mailhot M., Lavoie A., Berthiaume Y., Rabasa-Lhoret R.
Relationship between vitamin D levels and glucose tolerance in an adult population with cystic fibrosis
Diabetes & Metabolism 2016; 42: 135 - 138

Coriati A., Ziai S., Lavoie A., Berthiaume Y., Rabasa-Lhoret R.
The 1-h oral glucose tolerance test glucose and insulin values are associated with markers of clinical deterioration in cystic fibrosis

Koilvula FNM., McLennan NH., Harper AGS., Kelly C.
Islet-intrinsic effects of CFTR mutation
Diabetologia 2016; 59: 1350 - 1355

Montanini L., Cirillo F., Smerieri A., Pisi G., Giardino L., d’Apolito M., Spaggiari C., Bernasconi S., Amarri S., Street ME.
HMGB1 Is Increased by CFTR Loss of Function, Is Lowered by Insulin, and Increases In Vivo at Onset of CFRD
Journal of Clinical Endocrinology & Metabolism 2016; 101: 1274 - 1281

Onady GM., Stoff A.
Insulin and oral agents for managing cystic fibrosis-related diabetes
Cochrane Database of Systematic Reviews 2016; : 4:CD004730

Prentice B., Hameed S., Verge CF., Ooi CY., Jaffe A., Widger J.
Diagnosing cystic fibrosis-related diabetes: current methods and challenges

Schneider MA., Bend M., Schmid C.
HbA1c: An effective screening tool for cystic fibrosis related diabetes?
Journal of Cystic Fibrosis 2016; 15: 261 - 262

Widger J., Hameed S., Ooi CY., Verge C.
Using HbA1c as a screening tool for Cystic Fibrosis Related Diabetes
Journal of Cystic Fibrosis 2016; 15: 263 - 264

Diagnosis

Rosenfeld M., Sontag MK., Ren CL.
Cystic Fibrosis Diagnosis and Newborn Screening
Pediatric Clinics of North America 2016; 63: 599 - +

Endocrinology

Blackman SM., Tangpricha V.
Endocrine Disorders in Cystic Fibrosis
Pediatric Clinics of North America 2016; 63: 699 - +

Lee SY., Cheshdachai S., Lee MJ., He XM., Tangpricha V., Braverman LE.
Thyroid Function in Patients with Cystic Fibrosis: No Longer a Concern?
Thyroid 2016; 26: 875 – 879

Epidemiology

Silva A., Amorim A., Azevedo P., Lopes C., Gamboa F.
Cystic Fibrosis - characterization of the adult population in Portugal
Revista Portuguesa de Pneumologia 2016; 22: 141 - 145
Stewart C., Pepper MS.  
Cystic fibrosis on the African continent  
Genetics in Medicine 2016; 18: 653 - 662

Vahedi L., Jabarpour-Bonyadi M., Ghojazadeh M., Hazrati H., Rafeey M.  
Association between Outcomes and Demographic Factors in an Azerbaijani Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 through 2014  
Iranian Red Crescent Medical Journal 2016; 18: 4:e29615

Exercise

Del Caro J., Lara B., Salinero JJ., Areces F., Ruiz-Vicente D., Gallo-Salazar C., Abian-Vicen J., Cacabelos R.  
CFTR genotype-related body water and electrolyte balance during a marathon  
Scandinavian Journal of Medicine & Science in Sports 2016; 26: 1036 -1044

Doelman WR., Takken T., Bronsveld I., Hulzebos EHJ.  
Relationship between lung function and Modified Shuttle Test performance in adult patients with cystic fibrosis: a cross-sectional, retrospective study  
Physiotherapy 2016; 102: 184 - 188

Hebestreit H., Arets HGM., Aurora P., Boas S., Cerny F., Hulzebos EHJ., Karila C., Lands L.C., Lowman JD., Swisher A., Urquhart DS.  
Validity and Reliability Concerns Associated with Cardiopulmonary Exercise Testing Young People with Cystic Fibrosis Reply  
Respiration 2016; 92: 63 - 64

Kriemler S., Radtke T., Christen G., Kerstan-Huber M., Hebestreit H.  
Short-Term Effect of Different Physical Exercises and Physiotherapy Combinations on Spontaneous Experctoration, Oxygen Saturation, and Lung Function in Young Patients with Cystic Fibrosis  
Lung 2016; 194: 659 - 664

Malamud AL., Ricard PEH.  
Feasibility of the Six-Minute Walk Test for Patients who have Cystic Fibrosis, are Ambulatory, and Require Mechanical Ventilation before Lung Transplantation  
Physical Therapy 2016; 96: 1468 - 1476

Saynor ZL., Barker AR., Oades PJ., Tomlinson OW., Williams CA.  
Validity and Reliability Concerns Associated with Cardiopulmonary Exercise Testing Young People with Cystic Fibrosis  
Respiration 2016; 92: 61 - 62

Vallier JM., Pelletier L., Poirier J.M., Deschenes Y., Martel S.  
Physiological Responses of the Modified Shuttle Test in Adults With Cystic Fibrosis  
Journal of Cardiopulmonary Rehabilitation and Prevention 2016; 36: 288 - 292

Van IJzendoorn H., Wheatley CM., Baker SE., Morgan WJ., Snyder EM.  
The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis  
Heart & Lung 2016; 45: 283 – 290

Gastroenterology

Breddy J., Zidar N., Jorcu J., Orel R.  
Morphological and Functional Assessment of Oesophageal Macosa Integrity in Children With Cystic Fibrosis  

Corral JE., Dye CW., Mascarenhas MR., Barkin JS., Salathe M., Moshiere B.  
Is Gastroparesis Found More Frequently in Patients with Cystic Fibrosis? A Systematic Review  
Scientifica 2016; : ArNo: 2918139

Demeyer S., De Boeck K., Witters P., Cosaert K.  
Beyond pancreatic insufficiency and liver disease in cystic fibrosis  
European Journal of Pediatrics 2016; 175: 881 - 894

Hatzigourou E., Kamproras A., Sidiropoulou M., Markou A., Anastasiou A., Tsanakas J.  
Pancreatic Cystosis in Two Adolescents with Cystic Fibrosis  
Case Reports in Pediatrics 2016; : ArNo: 5321785

Howlett C., Ronan NJ., NicChroinin M., Mullen D., Plant BJ.  
Partial restoration of pancreatic function in a child with cystic fibrosis  
Lancet Respiratory Medicine 2016; 4: E21 - E22

Gene Therapy

Karda R., Buckley S.M., Waddington S.N.  
Gene Therapy with Adeno-associated Virus for Cystic Fibrosis  
American Journal of Respiratory and Critical Care Medicine 2016; 193: 234 - 236

General Review

VanDevanter DR., Kahle JS., O'Sullivan AK., Sikirica S., Hodgkins PS.  
Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment  

Genetics

Diana A., Polizzi AM., Santostasi T., Ratcliff L., Pantaleo MG., Leonetti G., Iusco DR., Gallo C., Conese M., Manca A.  
The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies  
Journal of Human Genetics 2016; 61: 473 - 481

Gajbhiye R., Kumaraswamy R., Khole V.  
The clinical phenotype and possible implications for cystic fibrosis  

Shah R., Kumaraswamy R., Khole V.  
The novel complex allele [A238V;F508del] of the CFTR gene: clinical phenotype and possible implications for cystic fibrosis etiological therapies  
Journal of Human Genetics 2016; 61: 473 - 481

Jahangiri M., Khorasani A., Khorasani R., Kohl V.  
Cystic fibrosis transmembrane conductance regulator (CFTR) gene abnormalities in Indian males with congenital bilateral absence of vas deferens & renal anomalies  
Indian Journal of Medical Research 2016; 143: 616 - 623

Marson FAL., Bertuzzo CS., Ribeiro JD.  
Classification of CFTR mutation classes  
Lancet Respiratory Medicine 2016; 4: E37 - E38

Salinas DB., Sosnay PR., Azen C., Young S., Raraigh KS., Keens TG., Kharrazi M.  
Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California  
PloS One 2016; 11: 5:e0155624

Shahin WA., Mehaney DA., El-Falaki MM.  
Mutation spectrum of Egyptian children with cystic fibrosis  
Springerplus 2016; 5: ArNo: 686
Stanke F., Tümmler B.  
Classification of CFTR mutation classes  

Temurhan S., Tamay Z., Gurkan H., Akgil S., Ozeker D., Kekik C., Cagatay F., Aydin F., Guler N.  
The Effect of TGFB1 and CD14 Gene Polymorphisms on the Clinical Findings of Cystic Fibrosis in Turkish Patients  

Zomer-van Ommen DD., Vijftijgschild L.A.W., Kruijssenbrink E., Vonk AM., Dekkers JJ., Janssens HM., de Winter-de Groot KM., van der Ent CK., Beekman JM.  
Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids  

Growth & Development  
Kelly A., Schall J., Stallings VA., Zemel BS.  
Trabecular and cortical bone deficits are present in children and adolescents with cystic fibrosis  
*Bone* 2016; 90: 7 - 14

Low sodium status in cystic fibrosis-as assessed by calculating fractional Na+ excretion-is associated with decreased growth parameters  
*Journal of Cystic Fibrosis* 2016; 15: 400 - 405

Naydenova-Stoeva B.  
Markers of bone metabolism in patients with cystic fibrosis  
*Journal of IMAB* 2015; 21: 901 - 907

Stein L., Pacht C., Junge S., Kaeding J., Kuck M., Maassen N., Wittke T., Shushakov V.  
The role of daily physical activity and nutritional status on bone turnover in cystic fibrosis: a cross-sectional study  

Zhang Z., LindstromM.J., Farrell P.M., Lai H.J.  
The effect of daily physical activity and nutritional status on bone turnover in cystic fibrosis patients with mild liver involvement  

Immunology & Inflammation  
Averna M., Bavestrello M., Cresta F., Pedrazzi M., De Tullio R., Minucci L., Saporito B., Salamone F., Ponzemoli S., Melloni E.  
Abnormal activation of calpain and protein kinase C alpha promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients  
*Archives of Biochemistry and Biophysics* 2016; 604: 103 - 112

Balanced activation of calpain and protein kinase C alpha promotes a constitutive release of matrix metalloproteinase 9 in peripheral blood mononuclear cells from cystic fibrosis patients  
*Archives of Biochemistry and Biophysics* 2016; 604: 103 - 112

Boeck K., Vandamme P., Devreese B.  
Faecal proteomics: A tool to investigate dysbiosis and inflammation in patients with cystic fibrosis  
*Journal of Cystic Fibrosis* 2015; 14: 242 - 250

Laval J., Ralhan A., Hart D.  
Neutrophils in cystic fibrosis  
*Biological Chemistry* 2016; 397: 485 - 496

Le Moigne V., Gaillard JL., Herrmann JL.  
Vaccine strategies against cystic fibrosis pathogens  
*Human Vaccines & Immunotherapeutics* 2016; 12: 751 - 756

Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis  
*Journal of Innate Immunity* 2016; 8: 330 - 349

Poghosyan A., Patel JK., Clifford RL., Knox AJ.  
Epigenetic dysregulation of interleukin 8 (CXCL8) hypersecretion in cystic fibrosis airway epithelial cells  
*Biochemical and Biophysical Research Communications* 2016; 476: 431 - 437

Pradenas GA., Ross BN., Torres AG.  
Burkholderia cepacia Complex Vaccines: Where Do We Go from here?  
*Vaccines* 2016; 4: 2:10

Prentice B., McKay K., Selvadurai H., Robinson PD., Abel F., Fitzgerald DA.  
Question 6: Is there a role for Mannose-Binding Lectin measurement in Cystic Fibrosis management?  
*Paediatric Respiratory Reviews* 2016; 19: 38 – 40

Liver Disease  
Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement  

Lemaître C., Dominique S., Billoud E., Eliezer M., Montialoux H., Quillard M., Riachi G., Koning E., Morisse-Pradier H., Savoye G., Savoye-Collet C., Goria O.  
Relevance of 3D Cholangiography and Transient Elastography to Assess Cystic Fibrosis-Associated Liver Disease?  
*Canadian Respiratory Journal* 2016; : ArNo: 4592702

Palaniappan S.K., Than N.N., Moe S., van Mourik I., Thein A.W.  
Interventions for managing advanced liver disease in cystic fibrosis patients  
*Quarterly Journal of Medicine* 2016; 109: 1149 - 1158

Stajgis M., Walkowiak J.  
Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement  

Pratico AD., Pratico ER., Rotolo N., Salafia S., Franzonello C., Leonard S.  
Isolated liver disease in a patient with a CFTR genotype F508del/12TG- 5T and 470MV: A new face of an old disease  
*Annals of Hepatology* 2015; 14: 933 - 946

Stonebraker JR., Ooi CY., Pace RG., Corvol H., Knowles MR., Durie PR., Ling SC.  
Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis  
*Clinical Gastroenterology and Hepatology* 2016; 14: 1207 - 1215
Mycobacteria in Cystic Fibrosis Respiratory Samples
Culture-Independent Identification of Nontuberculous Mycobacteria
LM. Raskin L., LiPuma JJ., Caverly LJ., Carmody LA., Haig SJ., Kotlarz N., Kalikin LM., Raskin L., LiPuma JJ.

Microbiological profiles of sputum and gastric juice aspirates in Cystic Fibrosis patients

Cystic Fibrosis patients

European Respiratory Journal 2016; 47: 1575 - 1577

Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year case-control study

European Respiratory Journal 2016; 47: 446 - 450

Pandoraean pneumonia isolated from an Australian Patient with Cystic Fibrosis

Frontiers in Microbiology 2016; 7: ArNo: 692

A Burkholderia Type VI Effector Deamidates Rho GTPases to Activate the Pyrin Inflammasome and Trigger Inflammation in Cystic Fibrosis

Journal of Infection 2016; 73: 1 - 7

Identification and functional analysis of a bacteriocin, pyocin S6, with ribonuclease activity from a Pseudomonas aeruginosa cystic fibrosis clinical isolate

Microbiology Open 2016; 5: 413 - 423

Non-typeable Haemophilus influenzae pernicious pericarditis in a child with cystic fibrosis

Pediatrics International 2016; 58: 607 - 609

Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis

Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis

Frontiers in Microbiology 2016; 7: ArNo: 1336

Candida albicans in cystic fibrosis: "Opening statements presented, let the trial begin"

Pediatric Pulmonology 2016; 51: 445 - 446

Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature

BMC Microbiology 2016; 16: ArNo: 122

Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention

ISME Journal 2016; 10: 1081 - 1091

Identification and functional analysis of a bacteriocin, pyocin S6, with ribonuclease activity from a Pseudomonas aeruginosa cystic fibrosis clinical isolate

Microbiology Open 2016; 5: 413 - 423

Non-typeable Haemophilus influenzae pernicious pericarditis in a child with cystic fibrosis

Pediatrics International 2016; 58: 607 - 609

Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis

Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis
Journal of Cystic Fibrosis 2016; 15: 186 - 191


Pulmonary Nontuberculous Mycobacteriosis and Chronic Lower Respiratory Tract Infections in Patients with Allergic Bronchopulmonary Mycysis without Cystic Fibrosis: Jani M., Matthe K., Azad RK. Internal Medicine 2016; 55: 1067 - 1070


Aspergillus infections in cystic fibrosis: King J., Brunel SF., Warris A. Journal of Infection 2016; 72:

Synthetic Cystic Fibrosis Sputum Medium Regulates Flagellar Biosynthesis through the flhF Gene in Burkholderia cenocepacia: Kumar B., Cardona ST. European Respiratory Journal 2016; 47: 1392 - 1401


Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis: Madan JC. Scientific Reports 2016; 6: ArNo: 24857


Chronic lung infection caused by Trichosporon mycotoxinivorans and tricosporn mucoides in an immunocompetent cystic fibrosis patient: Nguyen AT., Jones JW., Camara M., Williams P., Kane MA., Oglesby-Sherrouse AG. European Journal of Clinical Microbiology & Infectious Diseases 2016; 35: 947 - 953

Acute Scedosporium Apiospermum endobronchial infection in cystic fibrosis: Madan JC. Pediatric Infectious Disease Journal 2016; 35: 701 - 702


Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis: Madan JC. Scientific Reports 2016; 6: ArNo: 24857


Chronic lung infection caused by Trichosporon mycotoxinivorans and tricosporn mucoides in an immunocompetent cystic fibrosis patient: Nguyen AT., Jones JW., Camara M., Williams P., Kane MA., Oglesby-Sherrouse AG. European Journal of Clinical Microbiology & Infectious Diseases 2016; 35: 947 - 953


Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis: Madan JC. Scientific Reports 2016; 6: ArNo: 24857


Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis: Madan JC. Scientific Reports 2016; 6: ArNo: 24857


Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis: Madan JC. Scientific Reports 2016; 6: ArNo: 24857


Saunders RV, Modha DE, Claydon A, Gaillard EA. Chronic Aspergillus fumigatus colonization of the pediatric cystic fibrosis airway is common and may be associated with a more rapid decline in lung function. Medical Mycology 2016; 54: 537 - 543.


**Nutrition**


Oliver C., Watson H. Omega-3 fatty acids for cystic fibrosis. *Cochrane Database of Systematic Reviews* 2016; : 1:CD002201

Simon MISD., Forte GC., Pereira JD., Prociunoy EDA., Drehmer M. Validation of a Nutrition Screening Tool for Pediatric Patients with Cystic Fibrosis. *Journal of the Academy of Nutrition and Dietetics* 2016; 116: 813 - 818


**Physiotherapy**


**Psychosocial**


Campbell F., Biggs K., Aldiss SK., O’Neill PM., Clowes M., McDonagh J., While A., Gibson F. Transition of care for adolescents from paediatric services to adult health services. *Cochrane Database of Systematic Reviews* 2016; : 4:CD009794


Frederick C. Psychosocial Challenges/Transition to Adulthood. *Pediatric Clinics of North America* 2016; 63: 725 - +


Knudsen KB., Pressler T., Mortensen LH., Jarden M., Skov M., Quittner AL., Katzenstein T., Boisen KA. Associations between adherence, depressive symptoms and health-related quality of life in young adults with cystic fibrosis. *Springerplus* 2016; 5: ArNo: 1216


Pakhalé S., Baron J., Armstrong M., Tasca G., Gaudet E., Aaron SD., Cameron W., Balfour L.

Lost in translation? How adults living with Cystic Fibrosis understand treatment recommendations from their healthcare providers, and the impact on adherence to therapy

Patient Education and Counseling 2016; 99: 1319 - 1324

Sole A., Perez L., Vazquez L., Pastor A., Escriva J., Sales G., Hervas D., Glavnić AR., Quittner AL.

Patient-reported symptoms and functioning as indicators of mortality in advanced cystic fibrosis: A new tool for referral and selection for Lung transplantation

Journal of Heart and Lung Transplantation 2016; 35: 789 - 794

Solem CT., Vera-Lluch M., Liu SZ., Botteman M., Castiglione B.

Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis

Health and Quality of Life Outcomes 2016; 14: ArNo: 63

### Pulmonology

Beubler E., Fischer R., Untersteiner G., Strohmaier MA.

Influence of the Surfactant Tyloxapol on Mucociliary Clearance in Human Respiratory Cystic Fibrosis Cells

Pharmacology 2016; 98: 1 - 3

Brecelj J., Zidar N., Jeruc J., Orel R.

Morphological and Functional Assessment of Oesophageal Macosa Integrity in Children With Cystic Fibrosis


Chillappagari S., Muller C., Mahavadi P., Guenther A., Nahrlich L., Rosenblum J., Rubin BK., Henke MO.

A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation

Journal of Cystic Fibrosis 2016; 15: 325 - 331

Goetz DM., Singh S.

Respiratory System Disease

Pediatric Clinics of North America 2016; 63: 637 - +

Hamilos DL.

Chronic Rhinosinusitis in Patients with Cystic Fibrosis

Journal of Allergy and Clinical Immunology-in Practice 2016; 4: 605 - 612

Heltshoe SL., Szczesniak RD.

Forced expiratory volume in 1 second variability in cystic fibrosis - has the clinical utility been lost in statistical translation?

Journal of Pediatrics 2016; 172: 228

Kane M., Gonska T., Jensen R., Avolio J., Klingel M., Stanogjevic S., Ratjen F.

Lung clearance index response in patients with CF with class III CFTR mutations

Thorax 2016; 71: 476 - 477

Mastrigt E., Reyes-Reyes A., Brand K., Bhattacharya N., Urbach HP., Stubbis AP., de Jongst JC., Pijnenburg MW.

Exhaled breath profiling using broadband quantum cascade laser-based spectroscopy in healthy children and children with asthma and cystic fibrosis


Morgan WJ., Pasta DJ., Konstan MW.

Forced expiratory volume in 1 second variability in cystic fibrosis - has the clinical utility been lost in statistical translation? Reply

Journal of Pediatrics 2016; 172: 228 - 229

Moss A., Juarez-Colunga E., Nathoo F., Wagner B., Sagel S.

A comparison of change point models with application to longitudinal lung function measurements in children with cystic fibrosis

Statistics in Medicine 2016; 35: 2058 - 2073

Olszowiec-Chlebna M., Koniarek-Maniecka A., Stelmach W., Smejda K., Jerzynska J., Majak P., Bialasi M., Stelmach I.

Predictors of deterioration of lung function in Polish children with cystic fibrosis

Archives of Medical Science 2016; 12: 402 - 407

Quinn RA., Lim YW., Make TD., Whiteson K., Furlan M., Conrad D., Rohwer F., Dorrestein P.

Metabolomics of pulmonary exacerbations reveals the personalized nature of cystic fibrosis disease

PEERJ 2016; 4: ArNo: e2174

Radtke T., Puhlan MA., Hebestreit H., Kriemler S.

The 1-min sit-to-stand test A simple functional capacity test in cystic fibrosis?


Reicher JJ., Mohabir P., Rad E., Gayer G.

Increased prevalence of tracheal diverticula in cystic fibrosis patients

British Journal of Radiology 2016; 89: 1060:20150694

Smith D., Sovova K., Dryahina K., Dousova T., Drevinek P., Spanel P.

Breath concentration of acetic acid vapour is elevated in patients with cystic fibrosis


Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate


Stockley JA., Stockley RA.

Pulmonary Physiology of Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Alpha-1 Antitrypsin Deficiency Annals of the American Thoracic Society 2016; 13:

VanDevanter DR., Morris NJ., Konstan MW.

IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis


Wells JM., Farris RF., Gosdin TA., Dransfield MT., Wood ME., Bell SC., Rowe SM.

Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study

Lancet Respiratory Medicine 2016; 4: 636 – 645

### Radiology

Gergin O., Kawai K., MacDougall RD., Robson CD., Moritz E., Cunningham M., Adii E.

Sinus Computed Tomography Imaging in Pediatric Cystic Fibrosis: Added Value?

Otolaryngology-Head and Neck Surgery 2016; 155: 160 - 165

Jonczyk-Potoczna K., Nowak JK., Madry E., Katulska K., Stezowska-Kubiak S., Moczko J., Lisowska A., Walkowiak J.

Smaller Width of the Pancreatic Duct During Secretin-Enhanced Magnetic Resonance Cholangiopancreatography in Pancreatic-Sufficient Cystic Fibrosis Patients

Pancreas 2016; 45: 1175 - 1183

Rottmanns U., Palmowski K., Wielputz M., Kahn N., Baroke E., Eberhardt R., Wege S., Wiebel M., Kreuter M., Herth FF., Mall MA.

Optical coherence tomography detects structural abnormalities of the nasal mucosa in patients with cystic fibrosis

Journal of Cystic Fibrosis 2016; 15: 216 - 222
Karahasanovic A., Thorsteinsson AL., Bjarnason NH., Eiken P.
Long-term leukopenia in a lung transplanted patient with cystic fibrosis treated with zoledronic acid: a case report
Osteoporosis International 2016; 27: 2621 - 2625

Lung transplantation for cystic fibrosis: differential characteristics and outcomes between children and adults

Pritchard J., Thakrar MV., Somayaji R., Surette MG., Rabin HR., Helmersen D., Lien D., Purighalla S., Waddell B., Parkins MD.
Epidemic Pseudomonas aeruginosa infection in patients with cystic fibrosis is not a risk factor for poor clinical Outcomes following lung transplantation
Journal of Cystic Fibrosis 2016; 15: 392 - 399

Ramos KJ., Quon BS., Poter KJ., Lease ED., Mayer-Hamblett N., Aitken ML., Goss CH.
Predictors of non-referral of patients with cystic fibrosis for lung transplant evaluation in the United States
Journal of Cystic Fibrosis 2016; 15: 196 - 203

Schmid FA., Benden C.
Special considerations for the use of lung transplantation in pediatrics
Special considerations for the use of lung transplantation in pediatrics

Liver and lung transplantation in cystic fibrosis: an adult cystic fibrosis centre's experience
Internal Medicine Journal 2016; 46: 852 - 854

Usatin DJ., Perito ER., Posselt AM., Rosenthal P.
American Journal of Transplantation 2016; 16: 1620 - 1625